title: [Quality challenge for immunohistochemistry: example of the ERBB-2 status in breast cancer. Group for Evaluation of Prognostic Factors in Immunohistochemistry in Breast Cancer (GEFPICS)].
authors.forename: F
authors.initials: F
authors.lastname: Penault-Llorca
authors.forename: J
authors.initials: J
authors.lastname: Jacquemier
authors.forename: V
authors.initials: V
authors.lastname: Le Doussal
authors.forename: J J
authors.initials: JJ
authors.lastname: Voigt
mesh_terms: D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents / Q000627:therapeutic use; D001943:Breast Neoplasms / Q000737:chemistry* / Q000188:drug therapy; D018849:Controlled Clinical Trials as Topic; D005260:Female; D006801:Humans; D007150:Immunohistochemistry / Q000592:standards*; D011786:Quality Control; D011933:Reagent Kits, Diagnostic; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000032:analysis*; D000068878:Trastuzumab
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; D011933:Reagent Kits, Diagnostic; D018719:Erb-b2 Receptor Tyrosine Kinases; D000068878:Trastuzumab